statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the...

Pyxis Oncology (NASDAQ:PYXS) vs. NewAmsterdam Pharma (NASDAQ:NAMS) Financial Survey

For the last three days, A.I.dvisor has detected that PYXS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Pyxis Oncology (PYXS, $4.81) Aroon Indicator entered a Downtrend on April 01, 2024.

Pyxis Oncology (PYXS, $4.24) Aroon Indicator entered a Downtrend on March 28, 2024.

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology (PYXS, $4.2) Aroon Indicator entered a Downtrend on March 27, 2024.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Pyxis Oncology obtains $8M payment for the sale of royalty rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's...

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Pyxis Oncology files to sell 10.46M common shares for holders...

Pyxis Oncology files to sell 10.46M common shares for holders

Pyxis Oncology (PYXS, $3.83) Aroon Indicator entered a Downtrend on March 26, 2024.

This is a signal that PYXS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Pyxis Oncology (PYXS, $3.83) RSI Indicator left the oversold zone on March 26, 2024

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Volume	818,440.00
52-Wk High	$6.85
52-Wk Low	$1.35

PYXS Pyxis Oncology Inc

About

Feed

News

Earnings

Fundamentals